Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2991691 | 0.86 | IKBKB (0.39) | HPGDALDH1A1NPC1TP53PKM | |
| SCHEMBL8553563 | 0.85 | NCF1 (0.38) | SMN1; SMN2HPGDALDH1A1NPC1TP53 | |
| SCHEMBL2998901 | 0.85 | ALDH1A1 (0.39) | SMN1; SMN2HPGDALDH1A1RAB9AMAPK1 | |
| SCHEMBL2990106 | 0.84 | CYP2C9 (0.40) | HPGDALDH1A1NPC1PKMRAB9A | |
| SCHEMBL8503292 | 0.84 | ALDH1A1 (0.38) | HPGDALDH1A1NPC1PKMRAB9A | |
| SCHEMBL2987646 | 0.83 | CYP2C9 (0.38) | HPGDALDH1A1NPC1PKMRAB9A | |
| SCHEMBL8088378 | 0.82 | ALDH1A1 (0.39) | HPGDALDH1A1NPC1PKMRAB9A | |
| SCHEMBL2991770 | 0.82 | LMNA (0.40) | HPGDALDH1A1CYP3A4LMNAMEN1 | |
| SCHEMBL2994288 | 0.82 | LMNA (0.40) | HPGDALDH1A1CYP3A4LMNAMEN1 | |
| SCHEMBL2982818 | 0.82 | LMNA (0.40) | HPGDALDH1A1CYP3A4LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357261-A1 | ARYL HYDROCARBON RECEPTOR LIGANDS AND THEIR ANALOGUES FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISORDERS | The University of Pittsburgh- of the Commonwealth System of Higher Education | 2023-11-09 | — | — | US | disclosed |
| US-20230357261-A1 | ARYL HYDROCARBON RECEPTOR LIGANDS AND THEIR ANALOGUES FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISORDERS | The University of Pittsburgh- of the Commonwealth System of Higher Education | 2023-11-09 | — | — | US | disclosed |
| US-8778975-B2 | Helicobacter pylori eradicating agent having inhibitory activity on gastric acid secretion | Link Geonomics, Inc. (JP) | 2014-07-15 | — | — | US | disclosed |
| EP-2103608-B1 | HELICOBACTER PYLORI ERADICATING AGENT HAVING INHIBITORY ACTIVITY ON GASTRIC ACID SECRETION | ARIGEN PHARMACEUTICALS INC (JP) | 2012-08-29 | — | — | EP | disclosed |
| US-20100173944-A1 | HELICOBACTER PYLORI ERADICATING AGENT HAVING INHIBITORY ACTIVITY ON GASTRIC ACID SECRETION | ARIGEN PHARMACEUTICALS, INC. (JP) | 2010-07-08 | — | — | US | disclosed |
| WO-2009137462-A2 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| EP-2103608-A1 | HELICOBACTER PYLORI ERADICATING AGENT HAVING INHIBITORY ACTIVITY ON GASTRIC ACID SECRETION | Arigen, Pharmaceuticals, Inc. (JP) | 2009-09-23 | — | — | EP | disclosed |
| EP-2049483-A2 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008055068-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357261-A1 | ARYL HYDROCARBON RECEPTOR LIGANDS AND THEIR ANALOGUES FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISORDERS | AHR, ARNT, MTNR1A | SMN1; SMN2 1637/4885HPGD 258/4885ALDH1A1 752/4885 |
| US-20100173944-A1 | HELICOBACTER PYLORI ERADICATING AGENT HAVING INHIBITORY ACTIVITY ON GASTRIC ACID SECRETION | GIPR, PGC, SLC10A2 | SMN1; SMN2 4682/4885HPGD 320/4885ALDH1A1 1629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.